Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

New treatments for macular degeneration may ... RGX-314 gene therapy only requires one injection, but it must be performed via a surgical procedure. This treatment is currently moving through ...

Among these conditions, retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are particularly prevalent. Recent advancements in gene therapy have opened new avenues for treating ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic macular edema with ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Age-related macular degeneration may cause a gradual reduction in your central vision over time, so you might not recognize ...

Visual prognosis depends on the type of retinal vein occlusion, its severity, degree of retinal ischemia or macular edema (ME ... The introduction of anti-VEGF therapy has altered treatment ...

discusses positive safety and efficacy data for NT-501 for macular telangiectasia type 2. NT-501 (revakinagene taroretcel, Neurotech Pharmaceuticals), an encapsulated cell therapy, was well ...

Retinal conditions such as Diabetic Retinopathy, Age-Related Macular Degeneration (AMD), Retinal ... depending on the stage of the disease. Laser therapy (photocoagulation) is often used to ...